Rigor Reviewed

Rigor-Reviewed Manuscript

Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.

Name: Αlpha¹ Rigor Record — Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.
Item: Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.
Rating: 100
Author: Αlpha¹

Ventorp F, Asp M, Olsson S, Lindahl J, Möller S, Svensson M, Ängeby F, Pravdinske A, Tjernberg J, Schrey S, Ståhl D, Magnusson V, Eliasson E, Agelii-Weber A, Stålhammar E, van Westen D, Deierborg T, Månsson KNT, Pizzagalli DA, Hammar Å, Tornberg ÅB, Björkstrand J, Lindqvist D

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported randomized controlled trial of pramipexole for anhedonic depression. The design is rigorous, statistical reporting is strong, and data/code availability is exemplary. The main weakness is an incomplete ethics statement (specific committee name/approval number not given), plus minor reporting gaps such as insufficient power analysis detail and a minor blinding-integrity discrepancy.

Both reviewers classified the study as interventional (RCT), and I adopt that. The evaluation covered the full text, including methods, results, and supplementary references. Not applicable criteria (e.g., animal housing, cell line authentication) were excluded. The reviewers diverged slightly on power analysis adequacy (Reviewer 1 adequate, Reviewer 2 inadequate) and on the ethics statement (both inadequate), which I reconciled as a warn for ethics and a minor gap for power analysis.

7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior studies on anhedonia, dopamine, and pramipexole, including a pilot study and a recent RCT. It acknowledges limitations of previous trials, such as insufficient dosing and heterogeneous populations, and explains how the current study addresses these (e.g., flexible dosing, transdiagnostic approach). The rationale linking dopamine agonism to anhedonia is well-articulated.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise with extensive prior work, a clear rationale, and addresses limitations of previous research.

Evidence

paraphrase[Introduction, paragraph 4]

“A pilot study conducted by our group provided preliminary evidence suggesting an antianhedonic effect of pramipexole, which was partly supported by a recent RCT.”

paraphrase[Discussion, paragraph 8]

“Given that some previous trials may have used insufficient doses, we implemented a flexible dosing strategy that allowed participants to reach a higher mean end dose compared to some earlier trials.”

paraphrase[Introduction, paragraph 3]

“Dopamine agonism has been proposed as a potential treatment target for a depression subtype marked by severe anhedonia.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on anhedonia, dopamine dysfunction, and pramipexole's potential, and clearly links this to the study's rationale and objectives.

Evidence

direct quote[Introduction, paragraph 3]

“A pilot study conducted by our group provided preliminary evidence suggesting an antianhedonic effect of pramipexole , which was partly supported by a recent RCT .”